If your idea of hair care is still "shampoo + conditioner," this data will force a rethink. The scalp is turning into skincare — exactly the way faces upgraded from "one cream for everything" to serum, eye cream, and mask a decade ago. It is happening faster, and the ceiling is higher.

The numbers, stripped of spin

Five data points define the inflection, and none of them require a leap of faith:

  1. Market size. China's hair and scalp care market (shampoo, conditioner, hair oil, scalp serum, hair mask) reached ¥54.1 billion (≈US$7.6B) in 2025, forecast ¥58.3 billion (≈US$8.2B) in 2026, +7.7% YoY. The growth is not in "washing" — it is in scalp serums, hair-essence serums, and professional repair, which carry most of the increment.
  2. Fastest segment. Anti-hair-loss / hair-retention demand reached US$4.87 billion (≈¥35B), up +22.3% YoY — the fastest-growing efficacy segment, well ahead of color repair, sensitive-scalp soothing, and kids' care (all 15%+). Legacy anti-dandruff is maturing at ~2%.
  3. New formats. Scalp serums and scalp-treatment sprays hit US$8.93 billion globally in 2026, +17.8% YoY. Scalp scrubs, night-repair sprays, and other new formats contribute ~28% of total increment — consumers are accepting "fine-grained scalp steps" fast.
  4. Channel shift. Online hair-care sales share broke 51% for the first time, overtaking offline supermarkets and salons; live commerce drove ~34.7% of the online increment. Social and content commerce are now the default cold-start channel.
  5. Awareness shift. "Scalp barrier repair" search volume grew +89% YoY in 2025; male consumers rose to ~38% of the market with growth first outpacing women. ~30% of consumers will pay a 30%+ premium for scalp products with ceramide, ectoin, and other actives.
Evidence note: figures are consolidated from public third-party industry reports (global and China hair/scalp care studies). Agency definitions of "scalp care" vary; treat the split numbers as directional, and the +22.3% / +17.8% as robust signals.

What the scalp buyer actually wants

The cliché is "anti-dandruff shampoo." The data says otherwise. Consumers now treat the scalp as skin: oiliness, itch, flakes, and thinning are read as scalp-barrier and microbiome imbalance. So the upgrade path is shampoo → scalp-cleansing + soothing; plus scalp serums, scalp ampoules, scalp scrubs, and pre-wash scalp oils. Ingredients moved from silicones and fragrance to caffeine, niacinamide, salicylic acid, ceramide, panthenol, madecassoside, bisabolol — familiar skincare actives.

In the US and EU, this maps to the "skinification of hair care" trend: think Head & Shoulders splitting into scalp-type lines, Kérastase and Ryo treating "scalp care" as the premium narrative, and DTC brands like The Ordinary-adjacent labs pushing single-actives (a caffeine scalp serum, a 2% salicylic pre-wash). The buyer converts on ingredient transparency + verifiable efficacy + a creator who looks like them — not a celebrity spot.

Three OEM entry paths

PathVehicleOEM notes
1. Anti-hair-loss lineHair-loss shampoo / scalp essenceCaffeine + botanical anti-loss actives; efficacy claims need human substantiation; higher MOQ
2. Scalp serumDropper / ampoule / sprayCeramide + panthenol + niacinamide + madecassoside; lowest capital entry, MOQ 500–1,000
3. Oil-control + sensitive-scalpOil-control shampoo / soothing serumSalicylic acid / OCT anti-dandruff; sulfate-free, silicone-free for the "clean" crowd

Formula guardrail: put the anti-inflammatory base first (madecassoside + panthenol + bisabolol), keep the hero active early in the INCI list (a trace of caffeine at position 15 is decoration, not function), and pick OCT over legacy zinc pyrithione. A competent hair care OEM manufacturer will specify active-retention and 3-month/6-month stability assays in the contract.

The compliance boundary

Scalp claims are a magnet for regulators, and the line differs by market. Under US FDA MoCRA cosmetics need facility registration but no pre-market approval — yet you cannot claim to "regrow hair" or "treat hair loss": that is a drug claim. Under EU 1223/2009 + CPNP every performance claim needs a substantiating dossier, and zinc pyrithione (ZPT) is being phased out under CMR 1B classification — switch to piroctone olamine (OCT). "Scalp microbiome / probiotic" claims are mostly conceptual and low-evidence; substantiate before you promise. Anti-hair-loss is a cosmetic appearance claim only where the local rule allows it; "grow new hair" crosses into medicine everywhere.

If you are a private label cosmetics manufacturer buyer sourcing a hair care OEM partner, brief the three-path framework, pilot at a low MOQ (500–1,000 units), and let repurchase rate — not the launch spike — tell you whether scalp care works for your brand.

🔗 Ready to sample an anti-hair-loss formula or a scalp serum? → https://www.quickoem.com/en/contact